LeMaitre Vascular Inc (LMAT) is Reiterated by Barrington Research to Outperform, Raises Price Target to $ 20

LeMaitre Vascular Inc (LMAT) was Reiterated by Barrington Research to “Outperform” according to the research note released today. The brokerage firm has raised the Price Target to $ 20 from a previous price target of $18.50 . Barrington Research advised their investors in a research report released on Jul 28, 2016.

On the company’s financial health, LeMaitre Vascular Inc reported $0.14 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Jul 27, 2016. Analyst had a consensus of $0.11. The company had revenue of $22.40 million for the quarter, compared to analysts expectations of $21.59 million. The company’s revenue was up 12.6% compared to the same quarter last year.

LeMaitre Vascular Inc opened for trading at $16.03 and hit $17.1 on the upside on Thursday, eventually ending the session at $16.59, with a gain of 13.40% or 1.96 points. The heightened volatility saw the trading volume jump to 3,34,791 shares. Company has a market cap of $305 M.

In a different news, on Jun 8, 2016, George W Lemaitre (Chairman and CEO) sold 19,189 shares at $15.03 per share price. According to the SEC, on Jun 8, 2016, Peter R Gebauer (President, International OP) sold 6,310 shares at $14.96 per share price. On Jun 7, 2016, Lawrence J Jasinski (director) sold 4,924 shares at $14.99 per share price, according to the Form-4 filing with the securities and exchange commission.

LeMaitre Vascular Inc. is a provider of medical devices for the treatment of peripheral vascular disease. The Company and its subsidiaries develop manufacture and market medical devices and implants used primarily in the field of vascular surgery. The Company’s product lines include valvulotomes balloon catheters carotid shunts biologic patches biologic grafts radiopaque marking tape anastomotic clips remote endarterectomy devices laparoscopic cholecystectomy devices vascular grafts angioscopes and powered phlebectomy devices. The Company develops manufactures and markets vascular devices to address the needs of vascular surgeons. Its portfolio of peripheral vascular devices consists of brand name products that are used in arteries and veins outside of the heart including the Expandable LeMaitre Valvulotome the Pruitt F3 Carotid Shunt VascuTape Radiopaque Tape and the XenoSure biologic patch.

LeMaitre Vascular Inc

Leave a Reply

LeMaitre Vascular Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on LeMaitre Vascular Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.